Amit Khurana of Dolat Capital anticipates limited market movement in the coming quarter due to headwinds, suggesting a cooling period before renewed buying. Upside potential is capped, while downside risk is protected. He advises a neutral stance on the pharma sector for FY26, citing normalizing tailwinds and US trade tariffs, but favors JB, Ajanta, Cipla, and Torrent.
Warren Buffett turns 96: Top 10 investing lessons from the Oracle of Omaha
As Warren Buffett turns 96 in his first birthday since stepping down as Berkshire Hathaway’s CEO, the piece revisits the investing principles behind his six-decade